

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3076497

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
DAVID FRENDEWEY	09/17/2014
WOJTEK AUERBACH	10/17/2014
DAVID M. VALENZUELA	10/17/2014
GEORGE D. YANCOPOULOS	09/27/2014
KA-MAN VENUS LAI	09/17/2014
RECEIVING PARTY DATA	
Name:	REGENERON PHARMACEUTICALS, INC.
Street Address:	777 OLD SAW MILL RIVER ROAD
City:	TARRYTOWN
State/Country:	NEW YORK
Postal Code:	10591-6706
PROPERTY NUMBERS Total: 3	
Property Type	Number
Application Number:	61638267
Application Number:	13870280
PCT Number:	US2013038165
CORRESPONDENCE DATA	
Fax Number:	(919)862-2260
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	9198622200
Email:	patent-mail@alston.com
Correspondent Name:	KELLY J. WILLIAMSON
Address Line 1:	4721 EMPEROR BLVD.
Address Line 2:	SUITE 400
Address Line 4:	DURHAM, NORTH CAROLINA 27703-8580
ATTORNEY DOCKET NUMBER:	057766/443520-KJW-KMM
NAME OF SUBMITTER:	KELLY J. WILLIAMSON
SIGNATURE:	/kelly j. williamson/
DATE SIGNED:	10/22/2014

PATENT

Total Attachments: 4

source=7950_Assignment#page1.tif

source=7950_Assignment#page2.tif

source=7950_Assignment#page3.tif

source=7950_Assignment#page4.tif

CONFIRMATORY ASSIGNMENT OF PROVISIONAL PATENT APPLICATION

JOINT

WHEREAS, David Frendewey of 330 E. 38th Street, Apt. 53A, New York, NY 10016; Wojtek Auerbach of 320 South Pleasant Avenue, Ridgewood, NJ 07450; David M. Valenzuela of 529 Giordano Drive, Yorktown Heights, NY 10598; George D. Yancopoulos of 1519 Baptist Church Road, Yorktown Heights, NY 10598; and Ka-Man Venus Lai of 127 West Main Street, Unit 201, Tarrytown, NY 10591; hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified patent applications:

Title	Filing date	Application No.
Nuclease-Mediated Targeting With Large Targeting Vectors	April 25, 2012	61/638,267
Nuclease-Mediated Targeting With Large Targeting Vectors	April 25, 2013	13/870,280
Nuclease-Mediated Targeting With Large Targeting Vectors	April 25, 2013	PCT/US2013/038165

WHEREAS, Regeneron Pharmaceuticals, Inc., a corporation of United States, located at 777 Saw Mill River Road, Tarrytown, NY 10591-6707, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

WHEREAS by virtue of employment agreement, Assignors have assigned all right title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention to Assignee;





FOR THE AVOIDANCE OF DOUBT, Assignors are executing the present assignment to confirm and supplement their prior employment agreement and prior assignment.

NOW THEREFORE, For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned , and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries

throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof. To the extent allowed by law, this confirmatory assignment to be effective nunc pro tunc at least as of April 25, 2012.

Assignors further agree that they will, without charge to Assignor, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: <u>17-Sep-2014</u>	 David Friendewey
Dated: <u>10/17/2014</u>	 Wojtek Auerbach
Dated: <u>10/17/2014</u>	 David M. Valenzuela
Dated: _____	_____ George D. Yancopoulos
Dated: <u>Sep 17' 2014</u>	 Ka-Mah Venus Lai

CONFIRMATORY ASSIGNMENT OF PROVISIONAL PATENT APPLICATION

JOINT

WHEREAS, David Frendewey of 330 E. 38th Street, Apt. 53A, New York, NY 10016; Wojtek Auerbach of 320 South Pleasant Avenue, Ridgewood, NJ 07450; David M. Valenzuela of 529 Giordano Drive, Yorktown Heights, NY 10598; George D. Yancopoulos of 1519 Baptist Church Road, Yorktown Heights, NY 10598; and Ka-Man Venus Lai of 127 West Main Street, Unit 201, Tarrytown, NY 10591; hereinafter referred to as "Assignors," are the inventors of the invention described and set forth in the below-identified patent applications:

Title	Filing date	Application No.
Nuclease-Mediated Targeting With Large Targeting Vectors	April 25, 2012	61/638,267
Nuclease-Mediated Targeting With Large Targeting Vectors	April 25, 2013	13/870,280
Nuclease-Mediated Targeting With Large Targeting Vectors	April 25, 2013	PCT/US2013/038165

WHEREAS, Regeneron Pharmaceuticals, Inc., a corporation of United States, located at 777 Saw Mill River Road, Tarrytown, NY 10591-6707, hereinafter referred to as "ASSIGNEE," is desirous of acquiring an interest in the invention and application and in any U.S. Letters Patent and Registrations which may be granted on any patent application claiming priority from the same;

WHEREAS by virtue of employment agreement, Assignors have assigned all right title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries throughout the world, and to claim the priority from the application as provided by the Paris Convention to Assignee;

FOR THE AVOIDANCE OF DOUBT, Assignors are executing the present assignment to confirm and supplement their prior employment agreement and prior assignment.

NOW THEREFORE, For good and valuable consideration, receipt of which is hereby acknowledged by Assignors, Assignors have assigned , and by these presents do assign to Assignee all right, title and interest in and to the invention and application and to all foreign counterparts (including patent, utility model and industrial designs), and in and to any Letters Patent and Registrations which may hereafter be granted on any patent application claiming priority from the same in the United States and all countries

throughout the world, and to claim the priority from the application as provided by the Paris Convention. The right, title and interest is to be held and enjoyed by Assignee and Assignee's successors and assigns as fully and exclusively as it would have been held and enjoyed by Assignors had this Assignment not been made, for the full term of any Letters Patent and Registrations which may be granted thereon, or of any division, renewal, continuation in whole or in part, substitution, conversion, reissue, prolongation or extension thereof. To the extent allowed by law, this confirmatory assignment to be effective nunc pro tunc at least as of April 25, 2012.

Assignors further agree that they will, without charge to Assignor, but at Assignee's expense, (a) cooperate with Assignee in the prosecution of U.S. Patent applications and foreign counterparts on the invention and any improvements, (b) execute, verify, acknowledge and deliver all such further papers, including applications and instruments of transfer, and (c) perform such other acts as Assignee lawfully may request to obtain or maintain Letters Patent and Registrations for the invention and improvements in any and all countries, and to vest title thereto in Assignee, or Assignee's successors and assigns.

IN TESTIMONY WHEREOF, Assignors have signed their names on the dates indicated.

Dated: _____
David Frendewey

Dated: _____
Wojtek Auerbach

Dated: _____
David M. Valenzuela

Dated: 9-27-14
George D. Yancopoulos

Dated: _____
Ka-Man Venus Lai